490 related articles for article (PubMed ID: 29500302)
1. Oral Therapies for Multiple Sclerosis.
Faissner S; Gold R
Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
[TBL] [Abstract][Full Text] [Related]
2. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Kretzschmar B; Pellkofer H; Weber MS
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
[TBL] [Abstract][Full Text] [Related]
3. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
4. New oral drugs for the treatment of multiple sclerosis.
Chard D; Trip A; Chataway J
Br J Hosp Med (Lond); 2016 Sep; 77(9):502-3. PubMed ID: 27640651
[No Abstract] [Full Text] [Related]
5. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
di Nuzzo L; Orlando R; Nasca C; Nicoletti F
Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
7. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
8. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
9. Ponesimod (Ponvory) for multiple sclerosis.
Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
[No Abstract] [Full Text] [Related]
10. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of three newly registered drugs for multiple sclerosis treatment.
Kasarełło K; Cudnoch-Jędrzejewska A; Członkowski A; Mirowska-Guzel D
Pharmacol Rep; 2017 Aug; 69(4):702-708. PubMed ID: 28550802
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
14. Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
Yoon EL; Cheong WL
Mult Scler Relat Disord; 2019 Feb; 28():104-108. PubMed ID: 30590239
[No Abstract] [Full Text] [Related]
15. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
16. Oral agents in multiple sclerosis.
Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E
Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S
Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119
[TBL] [Abstract][Full Text] [Related]
18. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
20. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]